Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialKohei Shitara, Min‐Hee Ryu, Lorenzo Fornaro et al.|The Lancet|2018Cited by 1.3k
Long-term outcome after perioperative chemotherapy and surgery for gastro-esophageal adenocarcinomaSusy Shim, Morten Ladekarl, Anders Christian Larsen et al.|ESMO Gastrointestinal Oncology|2025Cited by 1
P.37 Very elderly NSCLC patients above 75 years: Response to chemotherapy and improvement in quality of life is achievable to the same extent as for younger patients during platinum-based doublet chemotherapyJakob B. Sørensen, Anne Hildur Henriksen, Lene Bæksgaard|Critical Reviews in Oncology/Hematology|2007Cited by 0